Aehr Test Systems (AEHR) Dropped, So What Is Behind The Latest Attention?

Aehr Test Systems: what the new orders signal for investors

Aehr Test Systems (AEHR) recently announced about US$6 million in follow-on production orders from its lead hyperscale customer for testing next generation AI processors on its Sonoma platform.

The agreement extends Aehr Test Systems’ role in package level burn in for a second AI processor program, with the customer planning production ramp up in calendar 2027. This keeps attention on how this order fits into the company’s wider growth plans.

Aehr Test Systems’ share price has cooled in the very short term, with a 1-day move that declined 3.0% and a 7-day share price return that fell 10.3%, even as the 90-day share price return of 17.3% and year-to-date gain of about 3x keep longer term momentum in focus.

That backdrop comes after record quarterly bookings of US$60.7 million, an effective backlog of US$100.6 million and guidance for fiscal 2027 revenue in a range of US$130 million to US$150 million. The 1-year total shareholder return of 245.7% and 5-year total shareholder return of 336.8% underline how investors have already priced in a lot of expectation around AI driven demand and execution risks.

Spot 92 AI infrastructure stocks that, like Aehr Test Systems, are tied to the build out of AI processors and testing gear and could be positioned for the next wave of orders.

Aehr Test Systems now combines a big AI testing opportunity with a share price that has already moved sharply and recently pulled back. The real tension sits in the valuation. Are you still being paid enough for the risk?

Most Popular Narrative: 389.2% Overvalued

Aehr Test Systems last closed at $89.37, while the most followed valuation narrative pegs fair value at $18.27. This frames the current price as very stretched relative to that benchmark.

AEHR may still have attractive technology and exposure to semiconductor growth markets. But the capital allocation record deserves as much scrutiny as the product story.

See why 5 investors see Aehr Test Systems as 389% overvalued.

Result: Fair Value of $18.27 (OVERVALUED)

Still, Aehr Test Systems could surprise critics if insider selling moderates or if new multi year customer programs give investors clearer visibility on future demand.

Find out about the key risks to this Aehr Test Systems narrative.

Next Steps

Mixed signals on Aehr Test Systems so far. If you want to move quickly and decide for yourself, start with the balance of 1 key reward and 2 important warning signs.

Looking for more investment ideas beyond Aehr Test Systems?

Do not park your capital in a single story when there are other potential opportunities lined up for you on Simply Wall Street’s stock screener.

• Target resilient balance sheets and steady fundamentals by running your filters against our list of solid balance sheet and fundamentals (25 results).
• Hunt for potential value opportunities by scanning companies that show up in the 29 high quality undervalued stocks.
• Prioritise stability and income potential by reviewing the 8 dividend fortresses that might fit a yield focused portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com